Cara Therapeutics Inc (NASDAQ:CARA)’s share price fell 6% during trading on Monday . The stock traded as low as $17.63 and last traded at $17.68. 1,250,800 shares were traded during mid-day trading, an increase of 87% from the average session volume of 667,905 shares. The stock had previously closed at $18.81.
Several research firms have commented on CARA. BidaskClub upgraded Cara Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, April 30th. Zacks Investment Research downgraded Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, March 15th. Jefferies Financial Group began coverage on Cara Therapeutics in a research report on Wednesday, February 6th. They issued a “buy” rating and a $22.00 target price for the company. Finally, Bank of America began coverage on Cara Therapeutics in a research report on Tuesday, January 15th. They issued a “neutral” rating and a $19.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $24.03.
The company has a debt-to-equity ratio of 0.04, a current ratio of 3.40 and a quick ratio of 4.16. The stock has a market capitalization of $747.70 million, a PE ratio of -8.58 and a beta of 2.62.
In other news, CFO Mani Mohindru sold 16,041 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $19.12, for a total transaction of $306,703.92. Following the completion of the transaction, the chief financial officer now directly owns 24,067 shares in the company, valued at $460,161.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Derek T. Chalmers sold 9,792 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $17.04, for a total value of $166,855.68. Following the transaction, the chief executive officer now owns 943,996 shares of the company’s stock, valued at $16,085,691.84. The disclosure for this sale can be found here. Insiders have sold 49,533 shares of company stock valued at $911,310 over the last 90 days. 6.70% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Avondale Wealth Management raised its position in shares of Cara Therapeutics by 50.0% during the fourth quarter. Avondale Wealth Management now owns 3,000 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 1,000 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Cara Therapeutics by 36.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,601 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 964 shares during the period. Captrust Financial Advisors grew its stake in Cara Therapeutics by 40.0% during the fourth quarter. Captrust Financial Advisors now owns 4,900 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 1,400 shares during the period. Advisory Services Network LLC grew its stake in Cara Therapeutics by 39,086.4% during the fourth quarter. Advisory Services Network LLC now owns 8,621 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 8,599 shares during the period. Finally, NumerixS Investment Technologies Inc acquired a new stake in Cara Therapeutics during the fourth quarter worth approximately $121,000. Institutional investors own 61.09% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first reported by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://dakotafinancialnews.com/2019/05/14/cara-therapeutics-cara-trading-down-6.html.
About Cara Therapeutics (NASDAQ:CARA)
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.